Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precision BioSciences, Inc. (DTIL : NSDQ)

• Company Description    Precision BioSciences, Inc. operates as a genome editing company and develops therapeutic products primarily in the United States. The company offers ARCUS, a genome editing platform to cure cancers and genetic disorders. Precision BioSciences Inc. is based in Durham, North Carolina. Number of Employees: 108

• Price / Volume Information    Yesterday's Closing Price: $6.72 Daily Weekly Monthly 20 Day Moving Average: 154,159 shares Shares Outstanding: 11.79 (millions) Market Capitalization: $79.21 (millions) Beta: 1.72 52 Week High: $9.14 52 Week Low: $3.61 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.81% 29.91% 12 Week 45.46% 33.60% Year To Date 76.38% 52.74%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 302 EAST PETTIGREW STREET SUITE A-100 - DURHAM,NC 27701 USA ph: 919-314-5512 fax: - ir@precisionbiosciences.com http://www.precisionbiosciences.com

• General Corporate Information    Officers Michael Amoroso - President; Chief Executive Officer and Director Kevin Buehler - Chairman and Director John Alexander Kelly - Chief Financial Officer Melinda Brown - Director Stanley Frankel - Director Peer Information Precision BioSciences, Inc. (CORR.) Precision BioSciences, Inc. (RSPI) Precision BioSciences, Inc. (CGXP) Precision BioSciences, Inc. (BGEN) Precision BioSciences, Inc. (GTBP) Precision BioSciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74019P207 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/03/25 Share - Related Items Shares Outstanding: 11.79 Most Recent Split Date: 2.00 (0.03:1) Beta: 1.72 Market Capitalization: $79.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.19 Price/Cash Flow: - Price / Sales: 62.81 EPS Growth vs. Year Ago Period: -161.56% vs. Previous Quarter: 3.62% Sales Growth vs. Year Ago Period: -99.96% vs. Previous Quarter: -37.93% ROE 09/30/25 - - 06/30/25 - -176.47 03/31/25 - -69.26 ROA 09/30/25 - - 06/30/25 - -69.05 03/31/25 - -29.30 Current Ratio 09/30/25 - - 06/30/25 - 5.18 03/31/25 - 6.62 Quick Ratio 09/30/25 - - 06/30/25 - 5.18 03/31/25 - 6.62 Operating Margin 09/30/25 - - 06/30/25 - -7,159.79 03/31/25 - -83.06 Net Margin 09/30/25 - - 06/30/25 - -6,205.79 03/31/25 - -42.99 Pre-Tax Margin 09/30/25 - - 06/30/25 - -6,205.79 03/31/25 - -42.99 Book Value 09/30/25 - - 06/30/25 - 3.07 03/31/25 - 4.68 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.66 03/31/25 - 0.45 Debt-to-Capital 09/30/25 - - 06/30/25 - 39.63 03/31/25 - 31.17

Powered by Zacks Investment Research ©